SUMMARY AS OF:
6/26/2000--Introduced.
TABLE OF CONTENTS:
- Title I: Medicaid Prescription Drug Coverage for Low-Income Medicare
Beneficiaries
- Title II: Improved Access of Americans to Health Insurance Coverage
- Subtitle A: Access of Medicare Beneficiaries to Medicare+Choice Plans
- Subtitle B: Access of the Self-Employed
- Subtitle C: Improve the Coverage of Needy Children under the State
Children's
- Health Insurance Program (SCHIP) and the Medicaid Program
- Title III: Improved Access to Reasonably Priced Prescription Drugs
Drug Availability and Health Care Access Improvement Act of 2000 - Title
I: Medicaid Prescription Drug Coverage for Low-Income Medicare Beneficiaries
- Amends title XIX (Medicaid) of the Social Security Act (SSA) to require State
Medicaid plans to cover prescribed drugs for qualified Medicare (SSA title
XVIII) and other low-income Medicare beneficiaries. Provides full Federal
funding for such Medicaid coverage.
Title II: Improved Access of Americans to Health Insurance Coverage -
Subtitle A: Access of Medicare Beneficiaries to Medicare+Choice Plans -
Amends SSA title XVIII part C (Medicare+Choice) with respect to access to
Medicare+Choice plans through an increase in the minimum Medicare+Choice
capitation rate.
Subtitle B: Access of the Self-Employed - Amends the Internal Revenue
Code to provide for a tax deduction for the full amount of health insurance
costs of self-employed individuals.
Subtitle C: Improve the Coverage of Needy Children under the State
Children's Health Insurance Program (SCHIP) and the Medicaid Program -
Amends SSA titles XIX and XXI (State Children's Health Insurance Program)
(SCHIP) to require the respective State Medicaid and SCHIP plans to provide for
eligibility determinations, coordinated enrollment, and response to electronic
communications received through the national toll-free system the Secretary
shall establish.
(Sec. 221) Amends SSA titles XIX and XXI to provide financial incentives to
promote outreach and enrollment activities.
Amends SSA title XIX to provide for additional entities qualified to
determine Medicaid presumptive eligibility for low-income children.
(Sec. 222) Amends SSA title XXI with respect to coordination of pediatric
care within a family and reduction in the burden of administering cost-sharing
provisions under SCHIP.
(Sec. 223) Amends SSA title XIX and XXI to provide for automatic reassessment
of eligibility for Medicaid and SCHIP benefits in the case of a child who loses
eligibility for Medicaid or SCHIP benefits on the basis of changes in income,
assets, or age.
Amends SSA title XXI to authorize optional coverage of low-income, uninsured
pregnant women under a State SCHIP plan.
Amends SSA title XIX to give States the option to use an enhanced Federal
medical assistance percentage for coverage of additional pregnant women under
Medicaid.
Amends SSA titles XIX and XXI to give States the option to cover qualified
alien children under Medicaid and SCHIP.
Amends the Immigration and Nationality Act to except child Medicaid or SCHIP
assistance from the prohibition on seeking support from sponsors.
Amends SSA title XXI to provide for: (1) elimination of the funding offset
for exercise of the presumptive eligibility option under SCHIP; and (2)
coordination of it with the Maternal and Child Health Services program under SSA
title V.
Title III: Improved Access to Reasonably Priced Prescription Drugs -
Amends the Federal Food, Drug, and Cosmetic Act with regard to: (1) conditions
for Food and Drug Administration (FDA) warning notices about imported drugs; and
(2) consumer information in prescription drug advertising.
(Sec. 303) Directs the Secretary to inform patients of the existence of
programs operated by prescription drug manufacturers to provide such drugs to
patients without charge.
(Sec. 304) Expresses the sense of the Congress that: (1) the increased merger
of drug manufacturers has resulted in a decrease in price competition in the
prescription drug market and increased the potential for collusion in setting
prices; and (2) the Antitrust Division of the Department of Justice and the
Federal Trade Commission should give increased scrutiny to the anti-competitive
effects of such mergers.